Midway through trading Thursday, the Dow traded up 0.16% to 26,047.56 while the NASDAQ rose 0.51% to 7,832.53. The S&P also rose, gaining 0.31% to 2,889.11.
Leading and Lagging Sectors
Energy shares rose 1.1% on Thursday. Meanwhile, top gainers in the sector included Frontline Ltd. FRO 11.13%, up 12%, and Tellurian Inc TELL 10.2%, up 7%.
In trading on Thursday, health care shares fell by 0.2%.
RH RH 19.66% reported better-than-expected earnings for its first quarter and raised FY2019 guidance.
RH on Wednesday afternoon reported quarterly earnings of $1.85 per share, which beat the analyst consensus estimate of $1.55. The company reported quarterly sales of $598.421 million, which beat the analyst consensus estimate of $586.62 million.
The company also raised FY2019 guidance from $8.01-$8.69 to $8.76-$9.27 versus $8.40 estimates.
Equities Trading UP
Coda Octopus Group, Inc. CODA 39.75% shares shot up 36% to $13.17 after the company reported better-than-expected Q2 EPS and sales results.
Shares of Red Robin Gourmet Burgers, Inc. RRGB 29.3% got a boost, shooting up 29% to $32.95 following news Vintage Capital has suggested the company's Board conduct a review of strategic alternatives. The firm said it would be prepared to offer $40 per share for Red Robin following confirmatory due dilligence.
OpGen, Inc. OPGN 25.33% shares were also up, gaining 26% to $0.5347 after the company announced new data which showed clinical utility for antibiotic-resistant urinary tract infection patient management.
Equities Trading DOWN
Savara Inc. SVRA 75.4% shares tumbled 75% to $2.6450. Savara said a Phase 3 study dubbed IMPALA that evaluated its Molgradex for the treatment of autoimmune alveolar pulmonary proteinosis, or aPAP, did not meet its primary endpoint. An average A-aDO2 improvement of 12.1 mmHg was observed in the continuous dosing compared to an 8.8 mmHg improvement in the placebo arm, with an estimated 4.6 mmHg treatment difference suggesting the primary endpoint was not met.
Shares of Arcadia Biosciences, Inc. RKDA 32.4% were down 33% to $3.96 after the company announced a direct offering of 1.49 million shares at $5.035 per share.
Hemispherx Biopharma, Inc. HEB 21.48% was down, falling 25% to $5.07 after the company announced the first patient has been treated in the Phase 2 recurrent ovarian cancer program evaluating Ampligen in combination with Pembrolizumab and Cisplatin.
Silver traded up 0.4% Thursday to $14.805, while copper rose 0.2% to $2.6585.
European shares were higher today. The eurozone’s STOXX 600 rose 0.19%, the Spanish Ibex Index rose 0.11%, while Italy’s FTSE MIB Index climbed 0.77%. Meanwhile, the German DAX gained 0.4%, and the French CAC 40 rose 0.1% while UK shares rose 0.1%.
Initial jobless claims increased 3,000 to 222,000 last week. However, economists were expecting a reading of 216,000.
The import price index fell 0.3% for May, while export prices declined 0.2% for May.
Domestic supplies of natural gas climbed 102 billion cubic feet for the week ended June 7, the U.S. Energy Information Administration reported. However, analysts projected a gain of 108 billion cubic feet.
Data on money supply for the recent week will be released at 4:30 p.m. ET.
Benzinga does not provide investment advice. All rights reserved.